NCT05685602 2026-04-13
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
19 trialsNCT06958328 2026-04-08
LAP100
NRG Oncology
Phase 3 Recruiting
NCT06483555 2026-04-01
PANGEA
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT06998940 2026-03-27
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
Phase 3 Recruiting
NCT07049055 2026-02-27
Carolyn-USA
Engeneic Pty Limited
Phase 1/2 Recruiting
NCT04115163 2026-02-11
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT07226856 2025-12-22
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
Mayo Clinic
Phase 2 Recruiting
NCT04858009 2025-12-16
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
Mayo Clinic
Phase 2 Recruiting
NCT06385925 2025-12-15
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Tyligand Pharmaceuticals (Suzhou) Limited
Phase 1/2 Recruiting
NCT06783140 2025-12-05
PLATINUM-CAN
University Health Network, Toronto
Phase 2/3 Recruiting
NCT04158635 2025-08-19
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT06423326 2025-07-30
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Emory University
Phase 2 Recruiting
NCT05451043 2025-06-26
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT04543071 2025-06-19
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Columbia University
Phase 2 Recruiting
NCT05776524 2025-03-25
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
THERABIONIC INC.
Phase 2 Recruiting
NCT05841420 2025-01-29
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
Aalborg University Hospital
Phase 2 Recruiting
NCT06491472 2024-07-09
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT06196788 2024-03-21
PTCA199-9
Fudan University
Phase 2 Recruiting
NCT06017284 2023-11-24
PTCA199-5
Fudan University
Phase 3 Recruiting